JP2017503842A5 - - Google Patents

Info

Publication number

JP2017503842A5

JP2017503842A5 JP2016548172A JP2016548172A JP2017503842A5 JP 2017503842 A5 JP2017503842 A5 JP 2017503842A5 JP 2016548172 A JP2016548172 A JP 2016548172A JP 2016548172 A JP2016548172 A JP 2016548172A JP 2017503842 A5 JP2017503842 A5 JP 2017503842A5

Authority

JP

Japan

Prior art keywords

pharmaceutical composition

composition according

cell lymphoma

therapeutic agent

hodgkin

Prior art date

2015-01-23

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 16
• 239000013543 active substance Substances 0.000 claims description 15
• 239000003814 drug Substances 0.000 claims description 15
• 239000000203 mixture Substances 0.000 claims description 15
• 229940124597 therapeutic agent Drugs 0.000 claims description 15
• 229950002889 apilimod Drugs 0.000 claims description 12
• HSKAZIJJKRAJAV-KOEQRZSOSA-N n-[(e)-(3-methylphenyl)methylideneamino]-6-morpholin-4-yl-2-(2-pyridin-2-ylethoxy)pyrimidin-4-amine Chemical compound CC1=CC=CC(\C=N\NC=2N=C(OCCC=3N=CC=CC=3)N=C(C=2)N2CCOCC2)=C1 HSKAZIJJKRAJAV-KOEQRZSOSA-N 0.000 claims description 12
• 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 claims description 10
• 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 10
• 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 8
• OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 8
• 229960004528 vincristine Drugs 0.000 claims description 8
• OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 8
• 229960004679 doxorubicin Drugs 0.000 claims description 7
• OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims description 6
• 229960005205 prednisolone Drugs 0.000 claims description 6
• 239000002177 L01XE27 - Ibrutinib Substances 0.000 claims description 5
• 239000002552 dosage form Substances 0.000 claims description 5
• XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 claims description 5
• 229960001507 ibrutinib Drugs 0.000 claims description 5
• HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims description 4
• GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims description 4
• 229960005167 everolimus Drugs 0.000 claims description 4
• 229960004641 rituximab Drugs 0.000 claims description 4
• 229940099039 velcade Drugs 0.000 claims description 4
• FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 claims description 3
• 208000003950 B-cell lymphoma Diseases 0.000 claims description 3
• 102000004243 Tubulin Human genes 0.000 claims description 3
• 108090000704 Tubulin Proteins 0.000 claims description 3
• 229940100198 alkylating agent Drugs 0.000 claims description 3
• 239000002168 alkylating agent Substances 0.000 claims description 3
• 239000011230 binding agent Substances 0.000 claims description 3
• UKTAZPQNNNJVKR-KJGYPYNMSA-N chembl2368925 Chemical compound C1=CC=C2C(C(O[C@@H]3C[C@@H]4C[C@H]5C[C@@H](N4CC5=O)C3)=O)=CNC2=C1 UKTAZPQNNNJVKR-KJGYPYNMSA-N 0.000 claims description 3
• 239000003246 corticosteroid Substances 0.000 claims description 3
• 229960003413 dolasetron Drugs 0.000 claims description 3
• 230000000694 effects Effects 0.000 claims description 3
• 229960003727 granisetron Drugs 0.000 claims description 3
• MFWNKCLOYSRHCJ-BTTYYORXSA-N granisetron Chemical compound C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-BTTYYORXSA-N 0.000 claims description 3
• 239000000138 intercalating agent Substances 0.000 claims description 3
• 229960005343 ondansetron Drugs 0.000 claims description 3
• 229960002131 palonosetron Drugs 0.000 claims description 3
• CPZBLNMUGSZIPR-NVXWUHKLSA-N palonosetron Chemical compound C1N(CC2)CCC2[C@@H]1N1C(=O)C(C=CC=C2CCC3)=C2[C@H]3C1 CPZBLNMUGSZIPR-NVXWUHKLSA-N 0.000 claims description 3
• PHUTUTUABXHXLW-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 claims description 3
• 229960002508 pindolol Drugs 0.000 claims description 3
• RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 claims description 3
• 229960001534 risperidone Drugs 0.000 claims description 3
• -1 rituximab Chemical compound 0.000 claims description 3
• 208000011691 Burkitt lymphomas Diseases 0.000 claims description 2
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 2
• 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims description 2
• 229940009456 adriamycin Drugs 0.000 claims description 2
• 229960001334 corticosteroids Drugs 0.000 claims description 2
• 229960004397 cyclophosphamide Drugs 0.000 claims description 2
• 239000006186 oral dosage form Substances 0.000 claims description 2
• 229960004618 prednisone Drugs 0.000 claims description 2
• XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 2
• 239000008194 pharmaceutical composition Substances 0.000 claims 24
• 239000002253 acid Substances 0.000 claims 1
• 230000000306 recurrent effect Effects 0.000 claims 1
• 230000001225 therapeutic effect Effects 0.000 claims 1
• 238000000034 method Methods 0.000 description 19
• 206010028980 Neoplasm Diseases 0.000 description 6
• 201000011510 cancer Diseases 0.000 description 6
• 102100038028 1-phosphatidylinositol 3-phosphate 5-kinase Human genes 0.000 description 3
• 101710145421 1-phosphatidylinositol 3-phosphate 5-kinase Proteins 0.000 description 3
• 210000004027 cell Anatomy 0.000 description 2
• GAJWNIKZLYZYSY-OKUPSQOASA-N methanesulfonic acid;n-[(e)-(3-methylphenyl)methylideneamino]-6-morpholin-4-yl-2-(2-pyridin-2-ylethoxy)pyrimidin-4-amine Chemical compound CS(O)(=O)=O.CS(O)(=O)=O.CC1=CC=CC(\C=N\NC=2N=C(OCCC=3N=CC=CC=3)N=C(C=2)N2CCOCC2)=C1 GAJWNIKZLYZYSY-OKUPSQOASA-N 0.000 description 2
• 230000000144 pharmacologic effect Effects 0.000 description 2
• 206010025323 Lymphomas Diseases 0.000 description 1
• 108091000080 Phosphotransferase Proteins 0.000 description 1
• 108091030071 RNAI Proteins 0.000 description 1
• 230000001086 cytosolic effect Effects 0.000 description 1
• 210000001163 endosome Anatomy 0.000 description 1
• 239000012458 free base Substances 0.000 description 1
• 230000009368 gene silencing by RNA Effects 0.000 description 1
• 230000013632 homeostatic process Effects 0.000 description 1
• 230000005764 inhibitory process Effects 0.000 description 1
• 238000002347 injection Methods 0.000 description 1
• 239000007924 injection Substances 0.000 description 1
• 230000010189 intracellular transport Effects 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• 231100000225 lethality Toxicity 0.000 description 1
• 102000020233 phosphotransferase Human genes 0.000 description 1
• 230000007441 retrograde transport Effects 0.000 description 1
• 210000003412 trans-golgi network Anatomy 0.000 description 1
• 210000003934 vacuole Anatomy 0.000 description 1